Vanderson Rocha

Vanderson Rocha

Research

Our group, in collaboration with Service of Hematology and Cell therapy of the University of São Paulo, investigates the role of cell therapies to treat hematological diseases, including clinical results of allogeneic and autologous hematopoietic stem cell transplantation (HSCT). We are also starting to investigate therapies using genetic modified cells (CAR-T cells) to treat hematological diseases such as leukemias, lymphomas and multiple myeloma and genetic modified Hematopoietic Stem cells to treat sickle cell disease. Our aim is to perform “in vitro” and “in vivo” pre-clinical studies to validate gene delivery with viral vectors and non-viral vectors in lymphocytes, NK and macrophages. We are also interested in establishing a registry with rare hematological diseases such as amyloidoses, Waldenström macroglobulinemia, Erdheim-Chester Disease, Poems Sydrome, Castelman Disease, etc.

Keywords: Autologous and allogeneic HSCT, CAR-T cell therapy, Lymphomas, Leukemias and Multiple Myeloma

EDUCATION

Medical Degree Federal University of Minas Gerais

Master and PhD in Therapeutics Biotechnology, Paris University

Full professor of Hematology, University of Sao Paulo and University of Oxford

INVESTIGATION AREAS

Hematology

Oncology

ADITIONAL INFORMATION

Selected Publications

Fatobene G, Volt F, Moreira F, Mariano L, Chevallier P, Furst S, Labussière-Wallet H, de la Tour RP, Deconinck E, Cluzeau T, Russell N, Karakasis D, Forcade E, Ruggeri A, Gluckman E, Rocha V. Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. Blood Adv. 2020 Dec 22;4(24):6327-6335.
doi: 10.1182/bloodadvances.2020002258

Fatobene G, Rocha V, St Martin A, Hamadani M, Robinson S, Bashey A, Boumendil A, Brunstein C, Castagna L, Dominietto A, Finel H, Chalandon Y, Kenzey C, Kharfan-Dabaja M, Labussière-Wallet H, Moraleda JM, Pastano R, Perales MA, El Ayoubi HR, Ruggeri A, Sureda A, Volt F, Yakoub-Agha I, Zhang MJ, Gluckman E, Montoto S, Eapen M. Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. J Clin Oncol. 2020 May 10;38(14):1518-1526

Buss LF, Prete CA Jr, Abrahim CMM, Mendrone A Jr, Salomon T, de Almeida-Neto C, França RFO, Belotti MC, Carvalho MPSS, Costa AG, Crispim MAE, Ferreira SC, Fraiji NA, Gurzenda S, Whittaker C, Kamaura LT, Takecian PL, da Silva Peixoto P, Oikawa MK, Nishiya AS, Rocha V, Salles NA, de Souza Santos AA, da Silva MA, Custer B, Parag KV, Barral-Netto M, Kraemer MUG, Pereira RHM, Pybus OG, Busch MP, Castro MC, Dye C, Nascimento VH, Faria NR, Sabino EC. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science. 2021 Jan 15;371(6526):288-292.
doi: 10.1126/science. abe9728. Epub 2020 Dec 8.

Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opin Biol Ther. 2018 Feb;18(2):121-134.
doi: 10.1080/14712598.2018.1402002. Epub 2017 Nov 9.PMID: 29103317 Review./span>

Silveira DRA, Quek L, Santos IS, Corby A, Coelho-Silva JL, Pereira-Martins DA, Vallance G, Brown B, Nardinelli L, Silva WF, Velloso EDRP, Lucena-Araujo AR, Traina F, Peniket A, Vyas P, Rego EM, Bendit I, Rocha V. Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. Blood Adv. 2020 May 26;4(10):2339-2350.
doi: 10.1182/bloodadvances.2019001419.PMID: 32453839

More Content